SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

July 25, 2012 07:00 ET

Implant Sciences Wins Contracts to Supply Additional Explosives Trace Detectors to China for Use by China Police and Bomb Squads

WILMINGTON, MA--(Marketwire - Jul 25, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold 11 more Quantum Sniffer™ QS-H150 handheld explosives trace detectors to various police departments and bomb squads in China. The sale was made through the Company's in-country distributor and service provider, Beijing Ritchie Link, which continues to deliver superior service to the large installed base of QS-H150 users in China.

"Implant Sciences has been selling explosives trace detection equipment in China since 2005," commented Darryl Jones, Implant Sciences' Vice President of Sales and Marketing. "With hundreds of systems deployed in a wide variety of security applications across the country, our products have a well-established reputation for quality and reliability. It's that reputation that helps the QS-H150 maintain its position as one of the top choices in the Chinese security market."

Glenn D. Bolduc, Implant Sciences' President and CEO, added, "Our strong customer base and excellent distributor and service provider relationships form the foundation for our future development of the Chinese market. Implant Sciences' goal is to maintain its leadership role in the region as the market continues to evolve and grow."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risk that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by September 30, 2012; that if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; the risk that we continue to incur substantial operating losses and may never be profitable; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; the risk that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact